Cailong Pharmaceutical: a leading brain protector pharmaceutical company

The company is a pharmaceutical company engaged in the production and sale of chemicals in the fields of the nervous system, cardiovascular system, and digestive system. The company mainly produces, sells and has production approvals for pharmaceuticals such as tetrahexanose monosilicate ganglioside sodium injection (produced by Southwest Pharmaceutical), injectable brain protein hydrolysate (produced by Shanxi Pudde), injectable clindamycin phosphate, injectable pantoprazole sodium, and milinon injection. In terms of sales, the company's main products are concentrated on GM1 injections and injectable brain proteinhydrolysates, all of which are mainly cerebrovascular drugs. Both accounted for 94.14% of the company's total sales in 2016. In the first half of 2014-2017, the contribution of GM1 injections and injectable brain proteinhydrolysates (30 mg, 60 mg) to the overall gross profit of the company's main business remained stable.

Future highlights:

(1) The cerebrovascular drug market has maintained a steady growth trend. From 2009 to 2016, China's cerebrovascular chemical market sales maintained steady growth, rising from 21.699 billion yuan in 2009 to 72,865 billion yuan in 2016. The compound growth rate reached 18.89% over the past eight years, and the market growth is relatively good.

(2) The injectable brain protein hydrolysate produced by the company in collaboration with Shanxi Pude had a market share of 30.19%, 27.12% and 24.58% respectively in 2014-2016, ranking first and leading the brain protein hydrolysate preparation market in China. Furthermore, the company's share in the GM1 formulation market is gradually increasing, to 4.57%, 8.14%, and 9.64% respectively in 2014-2016.

(3) The company has established four major technology research and development platforms, and has mastered biological extraction, purification analysis, chiral drug synthesis technology, lipid microsphere formulation technology, preparation and identification technology for formulations, impurity separation, preparation and identification technology, etc., which can support the rapid development of the company's business and lay the technical foundation for the company to obtain production approvals for more APIs and formulations.

Risk warning: risk of adjustments to the medical insurance catalogue